A) Prolixin B) Risperdal C) Geodon D) Zyprexa
A) Clozaril B) Invega C) Abilify D) Zyprexa
A) Zyprexa B) Invega C) Seroquel D) Abilify
A) Seroquel B) Zyprexa C) Abilify D) Risperdal
A) Abilify B) Geodon C) Risperdal D) Seroquel
A) Quetiapine B) Clozapine C) Ziprasidone D) Olanzapine
A) Risperidone B) Ziprasidone C) Paliperidone D) Aripriprazole
A) Clozaril B) Geodon C) Risperdal D) Seroquel
A) Paliperidone B) Clozapine C) Aripiprazole D) Ziprasidone
A) Paliperidone B) Risperdone C) Quetiapine D) Olazapine
A) Risperidone and Paliperidone B) Aripiprazole and Paliperidone C) Clozapine and Risperadone D) Clozapine and Aripiprazole
A) 1-3 B) 2-5 C) 4-5 D) 1
A) 6 B) 12 C) 18 D) 24
A) FALSE B) TRUE
A) Foster patients' medication compliance B) Minimize side effects of medication C) Prevent relapse into another psychotic episode D) Develop more adaptive coping skills
A) one year after discontinuation of medication B) directly after discontinuation of medication C) several weeks after discontinuation of medication D) six months after discontinuation of medication
A) Clozaril B) Thorazine C) Artane D) Symmetrel
A) enhanced efficacy in treatment-resistant patients B) tardive dyskinesia more common C) weight gain more common D) increased effectiveness for positive, negative, and disorganized symptoms
A) Prochlorperazine B) Risperidone C) Clozapine D) Haloperiodol
A) Anticonvulsants B) Stimulants C) Anxiolitics D) Alcohol
A) Beta blockers B) Merperidine C) Alcohol D) Halperiodol
A) Beta blockers B) Anticonvulsants C) Antacids D) Nicotine
A) Beta blockers B) SSRIs C) Tricyclic antidepressants D) Alcohol
A) FALSE B) TRUE
A) Tobacco use B) Male gender C) Alcohol use D) Drug holidays
A) FALSE B) TRUE
A) Classic antipsychotic medications present less risk for the development of tardive dyskinesia than atypical antipsychotic medications. B) All antipsychotic drugs but Clozapine present a significant risk for the development of tardive dyskinesia. C) High potency antipsychotic drugs present greater risk for the development of tardive dyskinesia. D) The more frequent the dose of the antipsychotic medication, the greater the risk for the development of tardive dyskinesia.
A) Akinesia B) Acute dystonia C) Ataxia D) Akathesia
A) Neuroleptic Malignant Syndrome B) Agranulocytosis C) Gynecomastia D) Postural hypotension
A) TRUE B) FALSE
A) TRUE B) FALSE
A) agonize the normal dopamine-mediated inhibition of prolactin release. B) antagonize the normal dopamine-mediated inhibition of prolactin release. C) block D2 receptors in the pituitary gland and inhibit prolactin secretion. D) block D2 receptors in the pituitary gland and decrease prolactin secretion.
A) neuroendocrine changes B) hungry hungry hippos C) molecular structure D) receptor binding and DA turnover
A) Sleepykoaladones B) Thioxanthenenes C) Butyrophenones D) Phenothiazines
A) Potent; low; higher B) Weak; high; higher C) Potent; low; lower D) Weak; high; lower
A) Anhedonia B) Delusions C) Hallucinations D) Formal thought disorder
A) Neurological disorders B) Metabolic disorders C) Autoimmune diseases D) Endocrine disorders E) All of the above
A) Opioids B) Hallucinogens C) All of the above D) Alcohol E) Stimulants
A) TRUE B) FALSE
A) positive symptoms of Schizophrenia. B) disorganized symptoms of Schizophrenia. C) All of the above. D) negative symptoms of Schizophrenia.
A) blocking pre-synaptic dopamine receptors and/or inhibiting dopamine release. B) blocking post-synaptic dopamine receptors and/or inhibiting dopamine release. C) blocking post-synaptic dopamine receptors and/or inhibiting dopamine reuptake. D) blocking pre-synaptic dopamine receptors and/or inhibiting dopamine reuptake.
A) the drug reduces the normal dopamine-mediated activity in the striatum, which then enhances the cholinergic response that is normally inhibited by dopamine. B) the drug reduces the normal dopamine-mediated activity in the striatum, which then reduces the cholinergic response that is normally inhibited by dopamine. C) the drug increases the normal dopamine-mediated activity in the striatum, which then enhances the cholinergic response that is normally inhibited by dopamine. D) the drug increases the normal dopamine-mediated activity in the striatum, which then reduces the cholinergic response that is normally inhibited by dopamine.
A) increased release of dopamine B) increased tap dancing C) increased rates of firing D) increased rates of synthesis
A) piperideines B) piperazines C) aliphatics D) thioxanthenes
A) genecomastia B) all of the above C) galactorrhea D) menstrual irregularity
A) Benadryl (diphenhydramine) B) Artane (trihexphenidyl) C) Inapsine (droperiodol) D) Cogentin (benztropine) E) Symmetrel (amantadine)
A) TRUE B) FALSE
A) polypharmacy B) superior impact on positive symptoms C) actual impact at the biological level D) comparative lack of EPS
A) Clozaril B) Invega C) Abilify D) Haldol
A) Geodon B) Seroquel C) Clorazil D) Risperdal |